Business Context and Reporting Period
Entity note: The supplied filing is Arsanis, Inc.’s Form 10-Q for the quarter ended September 30, 2018, filed November 9, 2018. It is not identified in the filing as a filing by X4 Pharmaceuticals, Inc.
Arsanis was a clinical-stage biopharmaceutical company developing monoclonal antibody treatments for serious infectious diseases. It had no approved products and reported no product revenue. Following a futility determination, it discontinued the Phase 2 ASN100 trial and was reviewing strategic options. Its stated operating plan focused on reviewing the trial data, advancing preclinical ASN500, and supporting outlicensed ASN200 and ASN300 programs.
Financial Performance and Position
Amounts below are in U.S. dollars; financial statement figures are in millions unless otherwise noted.
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Product revenue | None | None | None | None |
| Research and development expense | $9.6 | $10.6 | $26.6 | $18.9 |
| General and administrative expense | $3.3 | $2.5 | $9.8 | $5.6 |
| Operating loss | $(12.8) | $(13.1) | $(36.4) | $(24.5) |
| Net loss | $(10.9) | $(11.6) | $(33.7) | $(22.7) |
| Operating cash used | — | $(33.8) | $(15.0) |
Grant and incentive income was $2.0 million in Q3 and $3.0 million year to date; it was reported as other income, not revenue. No meaningful revenue-based margin can be calculated. Q3 net loss per share was $0.76 versus $22.60 in 2017; year-to-date loss per share was $2.35 versus $44.22. The comparison is affected by the 2017 IPO and substantially different weighted-average share counts.
At September 30, 2018, cash and cash equivalents were $40.8 million, with an additional $0.6 million of restricted cash. Total assets were $45.9 million, current liabilities $8.9 million, and total liabilities $18.0 million. Debt principal was $12.8 million: $2.9 million under the SVB loan and $9.9 million under FFG loans. The balance sheet classified the SVB loan as current because of potential acceleration risk. On October 31, 2018, Arsanis paid approximately $3.1 million to satisfy all SVB obligations; FFG loans remained outstanding, with maturities from 2020 to 2023.
Material Changes Versus the Prior Comparable Period
- For the first nine months, R&D expense increased $7.7 million, mainly due to ASN100 trial and manufacturing costs and higher personnel-related expenses. Q3 R&D fell $1.0 million year over year as ASN100 spending declined.
- Year-to-date G&A rose $4.1 million, primarily reflecting public-company, personnel, insurance, director, legal, and accounting costs.
- Year-to-date net loss increased $11.0 million, while operating cash use more than doubled. Cash and cash equivalents fell from $76.8 million at year-end 2017 to $40.8 million.
- The company approved a workforce reduction affecting 19 positions, approximately 44% of staff. Estimated severance and retention costs were $2.8 million; $0.4 million had been recorded by September 30, with the remainder expected in Q4 2018 and Q1 2019.
Outlook, Risks, and Unusual Items
- The independent data review committee found ASN100 unlikely to meet its primary endpoint and recommended stopping enrollment. Arsanis ceased further clinical development pending review of the complete 154-patient dataset, expected in Q4 2018, and did not expect material ASN100 costs beyond that quarter.
- Management said September 30 cash was expected to fund operations, capital expenditures, and debt service into Q1 2020, based on its then-current operating plan and assumptions. The filing also cautioned that additional capital would be needed and might not be available on acceptable terms or at all.
- The company was considering strategic alternatives; no transaction or change in strategy was assured. ASN500 remained in preclinical development, and spending on it was expected to increase as development advanced.
- SVB had granted forbearance through October 31, 2018 after Arsanis entered ASN200 and ASN300 license agreements without prior lender consent and delivered compliance certificates that did not disclose the violations. SVB also had not agreed that stopping ASN100 did not constitute a material adverse change. The loan was subsequently repaid on October 31.
- Key risks include continued operating losses, financing needs and potential dilution, uncertain clinical and regulatory outcomes, reliance on collaborators and contract manufacturers, and possible repayment obligations under FFG agreements if their conditions are not met. The filing reported effective disclosure controls as of September 30, 2018 and no material change in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Confirm the issuer: this filing is for Arsanis, Inc., not X4 Pharmaceuticals, Inc.
- Review the final ASN100 trial analysis and any resulting changes to strategy, pipeline, or expected spending.
- Assess cash runway against actual post-quarter spending, restructuring payments, and management’s Q1 2020 estimate.
- Confirm the October 31 SVB repayment and track remaining FFG debt, maturities, and compliance conditions.
- Monitor ASN500 progress, collaborator activity on ASN200 and ASN300, and any strategic transaction or additional financing.